



**Contact:** Y. Ben Peng  
**Location:** Richland, WA, USA  
**Email:** [benpeng@xlscitech.com](mailto:benpeng@xlscitech.com)  
**Tel:** 509.531.3558  
**Website:** <http://xlscitech.com>



## Company Profile

**Industry Sector:** Medical Devices for treatment of soft tissue cancers.

**Company Overview:** XL Sci-Tech has been a pioneer in the timed-bioabsorbable microspheres that encapsulate radioisotopes. Its proprietary micro-fabrication process has made the company an innovator in breakthrough brachytherapy seeds for treatment of multiple soft tissue cancers ranging from liver cancer using shorter half-life beta emitting radioisotopes to prostate cancer using low energy gamma emitting radioisotopes.

**Target Market(s):** Brachytherapy Centers and Radiation Oncology Centers.

## Key Value Drivers

**Technology:** FlexSeeds™ are the first timed bioabsorbable brachytherapy seeds for prostate cancer in the world. They completely eliminate non-absorbable (metal) encapsulation shells and metal X-ray markers in the current prostate seeds. These seeds also offer major post-treatment options plus permit new treatment combinations for prostate cancer and other soft tissue cancers such as breast cancer.

**Competitive Advantage:** XL Sci-Tech's timed bioabsorbable encapsulation is the only encapsulation technology that distributes medical radioisotopes in a solid-state solution preventing any radioisotope leakage. FlexSeeds™ preserve all the desirable attributes of current prostate seeds while overcoming their major deficiencies. XL Sci-Tech has overcome formidable technological barriers and developed a protectable timed-bioabsorbable biomaterial platform. XL Sci-Tech can also benefit from an accelerated 510(K) FDA process that shortens the time to market and enhances adoption rates.

**Plan & Strategy:** Seeking strategic partners to accelerate human clinical trials.

\*Technology funded in part by the NIH SBIRs and being commercialized under the NIH-CAP.

## Management

**Leadership:**  
 Y. Ben Peng, President and CEO  
 Xingye Lei, Clinical Strategy Officer  
 Ronald Kathren, Radiation Safety Officer  
 Bernard Hansen: Chief Financial Officer

**Scientific Advisory Board:**  
 John Sylvester, M.D. (Invited): Radiation Oncologist, Seattle Prostate Institute  
 Timothy Mate, M.D. (Invited): Radiation Oncologist, Swedish Hospital, Seattle  
 Lu Liu: Professor of Nuclear Medicine, Southeast University, China  
 Ronald Kathren: Professor Emeritus of Pharmaceutical Sciences, Washington State University, Diplomat, American Board of Medical Physics.  
 Charles Hendricks: Professor Emeritus of Electrical Engineering and Nuclear Engineering, University of Illinois-Urbana.

## Product Pipeline

